Brokerages Set PepGen, Inc. (NASDAQ:PEPG) Price Target at $10.00

PepGen, Inc. (NASDAQ:PEPG) has earned a consensus recommendation of “Moderate Buy” from the five research firms that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation and four have given a buy recommendation to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $11.75.

Several equities analysts have recently commented on PEPG shares. HC Wainwright upped their target price on PepGen from $18.00 to $20.00 and gave the company a “buy” rating in a research report on Thursday, November 13th. Wall Street Zen upgraded shares of PepGen from a “sell” rating to a “hold” rating in a research note on Saturday, November 15th. Stifel Nicolaus lifted their price objective on shares of PepGen from $9.00 to $12.00 and gave the stock a “buy” rating in a research note on Thursday, September 25th. Guggenheim restated a “buy” rating and set a $6.00 target price on shares of PepGen in a research report on Wednesday, September 24th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of PepGen in a report on Wednesday, October 8th.

Insider Buying and Selling at PepGen

In related news, major shareholder Science Enterprises Plc Oxford bought 200,000 shares of PepGen stock in a transaction dated Tuesday, September 30th. The shares were bought at an average cost of $3.20 per share, with a total value of $640,000.00. Following the acquisition, the insider owned 4,955,388 shares in the company, valued at $15,857,241.60. This trade represents a 4.21% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Insiders own 4.60% of the company’s stock.

Hedge Funds Weigh In On PepGen

Several hedge funds have recently bought and sold shares of PEPG. RBF Capital LLC bought a new stake in PepGen during the second quarter worth $111,000. Adage Capital Partners GP L.L.C. lifted its position in shares of PepGen by 68.8% during the 1st quarter. Adage Capital Partners GP L.L.C. now owns 1,350,000 shares of the company’s stock worth $1,897,000 after buying an additional 550,000 shares during the last quarter. ADAR1 Capital Management LLC acquired a new stake in PepGen in the first quarter valued at about $29,000. Nuveen LLC acquired a new position in PepGen during the first quarter worth about $139,000. Finally, XTX Topco Ltd bought a new position in shares of PepGen in the first quarter worth about $25,000. 58.01% of the stock is owned by institutional investors.

PepGen Price Performance

PEPG stock opened at $5.47 on Tuesday. PepGen has a one year low of $0.88 and a one year high of $6.72. The stock has a market cap of $376.06 million, a price-to-earnings ratio of -1.94 and a beta of 1.90. The company has a fifty day moving average price of $5.11 and a two-hundred day moving average price of $2.90.

PepGen (NASDAQ:PEPG) last posted its earnings results on Wednesday, November 12th. The company reported ($0.52) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.11. Research analysts anticipate that PepGen will post -2.73 EPS for the current fiscal year.

PepGen Company Profile

PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.